Syndrome News and Research

RSS

SDSU researchers awarded NIH grant to understand how autism plays out across the lifespan

In the public consciousness, autism spectrum disorder only affects children. In truth, ASD is a lifelong condition. But how it affects older adults is a gaping unknown in autism research. Now, a new and significant grant from the National Institutes of Health will help researchers at San Diego State University understand how the disorder plays out across the lifespan.

29 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Actavis plc announced today that VIBERZI (eluxadoline) was approved by the Food and Drug Administration as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist.

28 May 2015

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults.

28 May 2015

GnRH infusion recommended for adolescent hypogonadotropic hypogonadodism

Pulsatile gonadotropin-releasing hormone may be more effective than human chorionic gonadotropin for the treatment of peripubescent boys with hypogonadotropic hypogonadodism, say Chinese researchers.

27 May 2015

Alizé Pharma presents clinical results from the AZP-531 program at the ADA 75th Scientific Sessions

Detailed data will be presented from the two Phase I trials conducted in 76 healthy volunteers and overweight or obese subjects...

26 May 2015

Clinical Frailty Scale can help predict readmission or death after hospital discharge in older patients

Frailer older patients are at higher risk of readmission to hospital or death within 30 days after discharge from a general internal medicine ward, but health care professionals can assess who is at risk using the Clinical Frailty Scale, according to a study in CMAJ (Canadian Medical Association Journal).

26 May 2015

New article shows link between head injuries and neurodegenerative disease in rugby union players

A new article publishing online today in the Quarterly Journal of Medicine has reported the first case showing an association between exposure to head injuries in rugby union players and an increased risk in neurodegenerative disease.

24 May 2015

New hope for patients suffering from most severe forms of anorexia nervosa

Anorexia Nervosa has the highest mortality rate of any mental illness. In its most severe form, victims face a devastating 4,500% increased risk for death. In the wake of the recent national attention on the limited treatment options available for these extreme cases, it is important for sufferers to know that help is available.

24 May 2015

Scientists uncover role of HTRA3 protease in Cockayne syndrome

Scientists from the Institut Pasteur and CNRS, in collaboration with scientists from the Institut Gustave Roussy and CEA, have succeeded in restoring normal activity in cells isolated from patients with the premature aging disease Cockayne syndrome. They have uncovered the role played in these cells by an enzyme, the HTRA3 protease.

22 May 2015

Omeros receives EMA CHMP positive opinion for Omidria for cataract, IOL replacement surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Omidria® (phenylephrine and ketorolac injection) 1%/0.3%.

22 May 2015

Merus Labs International acquires rights to manufacture, market specialty pharmaceutical products in multiple countries

Merus Labs International Inc. is pleased to announce that one of its wholly owned subsidiaries has signed a definitive agreement to acquire the rights to manufacture, market, and sell two established specialty pharmaceutical products in certain European and other markets.

22 May 2015

Studies refine amyloid imaging role in dementia

Two meta-analyses published in JAMA help to define the role of amyloid imaging in dementia.

21 May 2015

First-of-its-kind DNA bank aims at advancing research into genetics of stuttering

Scientists at the University of Alberta's Institute for Stuttering Treatment and Research want Albertans to give a spit -- five millilitres to be precise -- to help find the cause and a cure for stuttering.

21 May 2015

Discovery Lab enrolls first patient in phase 2a clinical trial of AEROSURF

Discovery Laboratories, Inc., a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today reported that the first patient has been enrolled in the next phase of its phase 2a clinical evaluation of AEROSURF, which is designed to evaluate the safety and tolerability of higher and repeat doses of aerosolized KL4 surfactant administered to premature infants 29 to 34 weeks gestational age (GA) who are receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS), compared to infants receiving nCPAP alone.

20 May 2015

Nerve cells guide each other during embryonic development

When nerve cells form in an embryo they do not start off in the right place but have to be guided to their final position by navigating a kind of molecular and cellular "map" in order to function properly. In a recent research study published in Nature Communications neurobiologist Sara Wilson, Umeå University, found that during embryonic development different parts of the nerve cell are important for guiding other nerve cells into their physical positions.

20 May 2015

Total costs of treatment for babies with neonatal abstinence syndrome on the rise

As more infants are born to mothers with dependence on prescription pain medications, the costs of treatment for babies with neonatal abstinence syndrome (NAS) have increased dramatically, suggests a report in the March/April issue of the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine.

20 May 2015

Study finds that nearly 35% of U.S. adults have metabolic syndrome

Nearly 35 percent of all U.S. adults and 50 percent of those 60 years of age or older were estimated to have the metabolic syndrome in 2011-2012, according to a study in the May 19 issue of JAMA.

19 May 2015

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo.

19 May 2015

Vitamin E helps build strong muscles

Body builders have it right: vitamin E does help build strong muscles, and scientists appear to have figured out one important way it does it.

19 May 2015

Syndrome News and Research

SDSU researchers awarded NIH grant to understand how autism plays out across the lifespan

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

GnRH infusion recommended for adolescent hypogonadotropic hypogonadodism

Alizé Pharma presents clinical results from the AZP-531 program at the ADA 75th Scientific Sessions

Clinical Frailty Scale can help predict readmission or death after hospital discharge in older patients

New article shows link between head injuries and neurodegenerative disease in rugby union players

New hope for patients suffering from most severe forms of anorexia nervosa

Scientists uncover role of HTRA3 protease in Cockayne syndrome

Omeros receives EMA CHMP positive opinion for Omidria for cataract, IOL replacement surgery

Merus Labs International acquires rights to manufacture, market specialty pharmaceutical products in multiple countries

Studies refine amyloid imaging role in dementia

First-of-its-kind DNA bank aims at advancing research into genetics of stuttering

Discovery Lab enrolls first patient in phase 2a clinical trial of AEROSURF

Nerve cells guide each other during embryonic development

Total costs of treatment for babies with neonatal abstinence syndrome on the rise

Study finds that nearly 35% of U.S. adults have metabolic syndrome

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Vitamin E helps build strong muscles

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News